Elucent Medical Announces $42.5M Series C Financing

April 10, 2024Client News

Gunderson Dettmer represented client Elucent Medical, a pioneering medical technology company, in its $42.5 million Series C financing led by Vensana Capital and RC Capital. Elucent Medical is a leading innovator in the field of oncologic surgical treatment solutions, dedicated to improving patient outcomes through precision and efficacy. The new capital will be used to further propel the development and commercialization of the company’s groundbreaking EnVisio® and SmartClip® technologies for tissue sparing oncologic surgery.

In the announcement of the transaction, Elucent Medical President and CEO Jason Pesterfield said, "We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures. With the support of our investors, we are poised to accelerate the commercialization of our EnVisio® and SmartClip® technologies, empowering healthcare providers with innovative tools to improve patient outcomes."

The Gunderson Dettmer deal team was led by Sogoal Salari and included Shu Hu, Jenny Whalen-Ball, Sahar Adora and Yue Yang.

Elucent Medical 
Vensana Capital
RC Capital